Figure 7.

Protected individuals in a rechallenge setting harbor augmented IpaB antibody FcR binding and Fc-mediated neutrophil phagocytosis

(A) Disease severity score of individuals in two consecutive challenges (n = 7).

(B and C) FcR binding levels (B) and antibody-mediated neutrophil phagocytosis (C) of IpaB- and OPS-specific antibodies before and after two consecutive challenges with S. flexneri 2a (n = 7).

(D) SBA titers before and after two consecutive challenges with S. flexneri 2a (n = 7).

^∗p < 0.05; ns, not significant.